Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) CFO James H. Mackaness sold 8,077 shares of the company’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $49.43, for a total transaction of $399,246.11. Following the completion of the sale, the chief financial officer now directly owns 119,172 shares in the company, valued at approximately $5,890,671.96. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Soleno Therapeutics Trading Up 1.4 %
SLNO opened at $49.63 on Friday. The company’s fifty day moving average price is $48.87 and its two-hundred day moving average price is $45.08. Soleno Therapeutics, Inc. has a 1-year low of $21.30 and a 1-year high of $55.56. The company has a market cap of $1.66 billion, a price-to-earnings ratio of -18.52 and a beta of -1.45.
Soleno Therapeutics (NASDAQ:SLNO – Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.57) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.06. As a group, equities analysts forecast that Soleno Therapeutics, Inc. will post -2.28 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Get Our Latest Stock Report on Soleno Therapeutics
Institutional Trading of Soleno Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in SLNO. Amalgamated Bank purchased a new stake in shares of Soleno Therapeutics in the second quarter valued at about $31,000. Victory Capital Management Inc. raised its holdings in shares of Soleno Therapeutics by 26.3% in the second quarter. Victory Capital Management Inc. now owns 10,727 shares of the company’s stock valued at $438,000 after purchasing an additional 2,236 shares during the last quarter. Cannon Global Investment Management LLC purchased a new stake in shares of Soleno Therapeutics in the first quarter valued at about $505,000. Sei Investments Co. raised its holdings in shares of Soleno Therapeutics by 22.0% in the first quarter. Sei Investments Co. now owns 12,577 shares of the company’s stock valued at $538,000 after purchasing an additional 2,264 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of Soleno Therapeutics in the second quarter valued at about $569,000. Hedge funds and other institutional investors own 97.42% of the company’s stock.
About Soleno Therapeutics
Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.
See Also
- Five stocks we like better than Soleno Therapeutics
- Why is the Ex-Dividend Date Significant to Investors?
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- What is the NASDAQ Stock Exchange?
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.